Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Michael C. Heinrich, Robin Lewis Jones, Margaret von Mehren, Sebastian Bauer, Yoon-Koo Kang, Patrick Schoffski, Ferry Eskens, Olivier Mir, Philippe Alexandre Cassier, Cesar Serrano, William D. Tap, Jonathan C. Trent, Piotr Rutkowski, Shreyaskumar Patel, Sant P. Chawla, Eyal Meiri, Teresa Zhou, Khalid Kevin Mamlouk, Maria Roche, Suzanne George
Institutions: Oregon Health & Science University, Portland VA Medical Center, OHSU Knight Cancer Institute, Institute of Cancer Research, Royal Marsden Hospital, Fox Chase Cancer Center, Essen University Hospital, Asan Medical Center, KU Leuven, Erasmus MC Cancer Institute, Institut Gustave Roussy, Centre Léon Bérard, Universitat Autònoma de Barcelona, Vall d'Hebron Institute of Oncology, Memorial Sloan Kettering Cancer Center, Sylvester Comprehensive Cancer Center, The Maria Sklodowska-Curie National Research Institute of Oncology, The University of Texas MD Anderson Cancer Center, Sarcoma Oncology Center, Cancer Treatment Centers of America, Blueprint Medicines (United States), Harvard University, Dana-Farber Cancer Institute
Language: English
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2967293120